Kanabo Group Plc
('Kanabo' or 'the Company')
KANABO'S CBD BASED 'SMOKING CESSATION" FORMULA MOVES CLOSER TO FULL PATENT APPROVAL
Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that focuses on the distribution of cannabis-derived products for medical patients and wellness CBD consumers, is pleased to announce that its unique CBD and nicotine formula has advanced from Patent Cooperation Treaty (PCT) phase to National Phase in the US, UK, and EU countries - the last phase before becoming an internationally approved patent.
Highlights;
· Kanabo's unique CBD and nicotine formula has advanced from PCT phase to National Phase - the last phase before becoming an internationally approved patent.
· The formula can be used to treat nicotine and tobacco addiction, with evidence suggesting the programme significantly reduces physical and psychological nicotine withdrawal effects by an average of 70 per cent.
· The formula is targeted at both the traditional smoking and e-cigarettes markets which are expected to reach £50mil over the coming years.
Avihu Tamir, CEO Kanabo, said, "Our unique patent pending CBD formulations and controlled and consistent delivery device, the VapePod, represents an excellent opportunity for governments to quickly end the reliance on tobacco for millions of citizens worldwide. Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world."
Kanabo's unique, high potency CBD and nicotine and standalone CBD formulas, delivered by their proprietary cartridges and VapePod, can be used to treat nicotine and tobacco addiction, with evidence so far suggesting the programme significantly reduces physical and psychological nicotine withdrawal effects. The formula is targeted at both the traditional smoking and e-cigarettes markets which are expected to reach £50mil over the coming years.
The application covers a unique new formula of specific naturally derived terpenes to allow the application of a very consistent and reproducible, high concentration of CBD throughout the life of the Kanabo cartridge. Initially, CBD is combined with Nicotine, which is then reduced over several weeks until there is zero Nicotine presence.
Tests with a handful of volunteers that participated in Kanabo's trial, have presented an average reduction of 70 per cent in their cigarette consumption and did not experience physical or psychological withdrawal effects.
As countries worldwide continue to seek measures to reduce tobacco smoking and even ban the use of tobacco products*, Kanabo's new IP offers a novel and effective way to reduce smoking and potentially complete withdrawal from Nicotine and e-cigarette addiction.
For further information, please visit http://www.kanabogroup.com or contact the following:
| Kanabo Group Plc | |
| Avihu Tamir, CEO
| Via Vox Markets |
| Peterhouse Capital Ltd | |
| Eran Zucker (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Lucy Williams / Charles Goodfellow (Corporate Broker)
| Tel: +44 (0)20 7469 0930 |
| Vox Markets (Investor Relations) | |
| Kat Perez |
About Kanabo Group Plc
Kanabo Group Plc is a medical cannabis and R&D company currently selling a range of wellness CBD Products across its Primary Markets and developing a range of and Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives. Learn more at https://www.voxmarkets.co.uk/listings/LON/KNB
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
